George M Yousef

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9029047/publications.pdf

Version: 2024-02-01

60

all docs

58 2,425 25 papers citations h-index

60

docs citations

h-index g-index

60 4453
times ranked citing authors

48

#	Article	IF	CITATIONS
1	OUP accepted manuscript. American Journal of Clinical Pathology, 2022, , .	0.7	2
2	ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade. Human Pathology, 2022, 120, 57-70.	2.0	3
3	Addressing the Diagnostic Miscommunication in Pathology. American Journal of Clinical Pathology, 2021, 156, 521-528.	0.7	7
4	Disruptive innovations in the clinical laboratory: catching the wave of precision diagnostics. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 546-562.	6.1	8
5	Journal Impact Factor: A Bumpy Ride in an Open Space. Journal of Investigative Medicine, 2020, 68, 83-87.	1.6	26
6	Prognostic urinary miRNAs for the assessment of small renal masses. Clinical Biochemistry, 2020, 75, 15-22.	1.9	18
7	Searching for prognostic biomarkers for small renal masses in the urinary proteome. International Journal of Cancer, 2020, 146, 2315-2325.	5.1	21
8	Knowledge Translation in Oncology. American Journal of Clinical Pathology, 2020, 153, 5-13.	0.7	7
9	Necessity and Challenges of Sample Preconcentration in Analysis of Multiple MicroRNAs by Capillary Electrophoresis. Analytical Chemistry, 2020, 92, 14251-14258.	6.5	9
10	Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. Pathology Research and Practice, 2020, 216, 153186.	2.3	11
11	Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. American Journal of Pathology, 2019, 189, 2046-2060.	3.8	6
12	The miR-200 family as prognostic markers in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 955-963.	1.6	25
13	Droplet digital PCR improves urinary exosomal miRNA detection compared to real-time PCR. Clinical Biochemistry, 2019, 67, 54-59.	1.9	60
14	Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass. American Journal of Pathology, 2019, 189, 2366-2376.	3.8	12
15	Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis. European Urology Focus, 2019, 5, 250-261.	3.1	4
16	Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood, 2018, 131, 1777-1789.	1.4	231
17	Manfred Schmitt (1947–2018). Biological Chemistry, 2018, 399, 923-924.	2.5	O
18	The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer. Biological Chemistry, 2018, 399, 973-982.	2.5	4

#	Article	IF	CITATIONS
19	Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy. European Urology Focus, 2018, 4, 740-748.	3.1	22
20	Direct Quantitative Analysis of Multiple microRNAs (DQAMmiR) with Peptide Nucleic Acid Hybridization Probes. Analytical Chemistry, 2018, 90, 14610-14615.	6.5	9
21	A miRNA-based classification of renal cell carcinoma subtypes by PCR and <i>in situ </i> hybridization. Oncotarget, 2018, 9, 2092-2104.	1.8	22
22	An integrated proteomic and peptidomic assessment of the normal human urinome. Clinical Chemistry and Laboratory Medicine, 2017, 55, 237-247.	2.3	28
23	Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Molecular Cancer, 2017, 16, 80.	19.2	275
24	Accurate MicroRNA Analysis in Crude Cell Lysate by Capillary Electrophoresis-Based Hybridization Assay in Comparison with Quantitative Reverse Transcription-Polymerase Chain Reaction. Analytical Chemistry, 2017, 89, 4743-4748.	6.5	21
25	MicroRNA Theranostics in Prostate Cancer Precision Medicine. Clinical Chemistry, 2016, 62, 1318-1333.	3.2	47
26	The Use of Targeted Therapies for Precision Medicine in Oncology. Clinical Chemistry, 2016, 62, 1556-1564.	3.2	10
27	Performance of residents using digital images versus glass slides on certification examination in anatomical pathology: a mixed methods pilot study. CMAJ Open, 2016, 4, E88-E94.	2.4	6
28	Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients. Clinical Chemistry, 2016, 62, 1002-1011.	3.2	54
29	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2016, 108, djw030.	6.3	144
30	KLK6â€regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. Molecular Oncology, 2016, 10, 993-1007.	4.6	24
31	The translational potential of microRNAs as biofluid markers of urological tumours. Nature Reviews Urology, 2016, 13, 734-752.	3.8	104
32	Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary, 2016, 19, 345-355.	2.9	72
33	Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell–Cell Communication in Renal Cell Carcinoma. European Urology Focus, 2016, 2, 210-218.	3.1	108
34	Omics for personalized medicine: defining the current we swim in. Expert Review of Molecular Diagnostics, 2016, 16, 719-722.	3.1	34
35	Proteomics and peptidomics: moving toward precision medicine in urological malignancies. Oncotarget, 2016, 7, 52460-52474.	1.8	61
36	miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. Journal of Molecular Diagnostics, 2015, 17, 136-144.	2.8	55

#	Article	IF	CITATIONS
37	Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes. Biomedicine and Pharmacotherapy, 2015, 70, 33-40.	5.6	19
38	Evaluation of human tissue kallikrein-related peptidases 6 and 10 expression in early gastroesophageal adenocarcinoma. Human Pathology, 2015, 46, 541-548.	2.0	7
39	Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2015, 185, 693-703.	3.8	68
40	Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. Human Pathology, 2015, 46, 673-680.	2.0	25
41	Personalized Medicine in Kidney Cancer: Learning How to Walk Before We Run. European Urology, 2015, 68, 1021-1022.	1.9	4
42	miRSNP-Based Approach Identifies a miRNA That Regulates Prostate-Specific Antigen in an Allele-Specific Manner. Cancer Discovery, 2015, 5, 351-352.	9.4	22
43	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. Molecular Therapy, 2015, 23, 1748-1758.	8.2	73
44	Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget, 2014, 5, 506-518.	1.8	87
45	Integrative Bioinformatics Analysis Reveals New Prognostic Biomarkers of Clear Cell Renal Cell Carcinoma. Clinical Chemistry, 2014, 60, 1314-1326.	3.2	50
46	Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. Oncoscience, 2014, 1, 709-724.	2.2	44
47	miRNA in Prostate Cancer: New Prospects for Old Challenges. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2014, 25, 79-98.	0.7	7
48	The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2013, 182, 1163-1170.	3.8	66
49	Genomic Medicine: New Frontiers and New Challenges. Clinical Chemistry, 2013, 59, 158-167.	3.2	59
50	Universal Drag Tag for Direct Quantitative Analysis of Multiple MicroRNAs. Analytical Chemistry, 2013, 85, 6518-6523.	6.5	40
51	Quantitative Proteomic Analysis in Metastatic Renal Cell Carcinoma Reveals a Unique Set of Proteins with Potential Prognostic Significance. Molecular and Cellular Proteomics, 2013, 12, 132-144.	3.8	73
52	Tumor suppressor effects for miR-215 identified through use of miRNA profiling in metastatic renal cell carcinoma Journal of Clinical Oncology, 2012, 30, 392-392.	1.6	0
53	Xp11.2 translocations in adult renal cell carcinomas with clear cell and papillary features Journal of Clinical Oncology, 2012, 30, 4613-4613.	1.6	0
54	Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biological Chemistry, 2010, 391, 411-23.	2.5	58

#	ARTICLE	IF	CITATIONS
55	Informatics for practicing anatomical pathologists: marking a new era in pathology practice. Modern Pathology, 2010, 23, 349-358.	5.5	71
56	The Human Kallikrein Gene Family: New Biomarkers for Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 165-187.	0.5	25
57	microRNAs: a new frontier in kallikrein research. Biological Chemistry, 2008, 389, 689-94.	2.5	24
58	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, 169, 361-364.	0.4	53